IFRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InflaRx NV (IFRX) is not a strong buy for a beginner, long-term investor at this time. While hedge funds are showing interest, the lack of significant positive catalysts, weak financial performance, and neutral technical indicators suggest holding off on investing until clearer growth signals emerge.
The MACD is slightly positive but contracting, RSI is neutral at 46.257, and moving averages are converging, indicating no clear trend. Key support and resistance levels are S1: 0.839, Pivot: 0.939, and R1: 1.038. The stock shows a 50% probability of minor declines in the short term.
Hedge funds have increased buying by 425.33% over the last quarter. Analyst Yatin Suneja maintains a Buy rating with a price target of $14, suggesting the stock is undervalued.
The stock has a 50% chance of declining slightly in the short term.
In Q4 2025, revenue remained flat YoY, net income dropped 100%, and EPS improved to -0.68 (up 655.56% YoY). Gross margin increased significantly but remains negative.
Guggenheim analyst Yatin Suneja lowered the price target from $22 to $14 but maintained a Buy rating, citing undervaluation and potential value from ANCA-associated vasculitis.
